Theravance has begun a TD-4208 dose ranging Phase IIb study in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Investigational inhaled long-acting muscarinic antagonist (LAMA) TD-4208, discovered using Theravance’s multivalent approach to drug design, is under development for the treatment of COPD.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Theravance research and early clinical development senior vice president Dr Mathai Mammen said some patients may prefer long-acting medicines delivered in the aqueous nebulised platform used in the study over handheld inhalation devices.

"Investigational inhaled long-acting muscarinic antagonist (LAMA) TD-4208, discovered using Theravance’s multivalent approach to drug design, is under development for the treatment of COPD."

"In addition, TD-4208 may offer these patients the convenience of once-a-day dosing compared to currently nebulised medicines which must be dosed multiple times daily," Mammen said.

The Phase IIb study is designed to assess the bronchodilatory effect, pharmacokinetics and safety and tolerability of multiple doses of TD-4208 in COPD patients.

See Also:

Around 60 patients are expected to be randomised with 22mcg, 44mcg, 88mcg, 175mcg, 350mcg or 700mcg doses of TD-4208 and placebo once each day through a nebuliser over five seven-day study periods in an incomplete crossover study design.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Trough forced expiratory volume in one second (FEV1) after the seventh dose of each treatment period is the primary endpoint of the study.

Secondary endpoints include measurements of FEV1: peak and area under the curve from 0 to 24 hours (AUC0-24), AUC0-12, and AUC12-24 after the seventh dose of each treatment period.

According to the preclinical study data, TD-4208 exhibited high specificity for muscarinic receptors, sustained activity in the lung after inhalation and minimal effects outside of the lung.